CellSHIELD® addresses critical challenges in cell and gene therapy manufacturing by reducing cost, improving efficiency, and supporting product safety. Its fully closed design ensures sterility and biocontainment, empowering biopharma companies and CDMOs to scale operations safely and efficiently. By simplifying processes and reducing training requirements, CellSHIELD® accelerates onboarding and enhances productivity, making it a game-changer for the industry.
The device is particularly well-suited for common applications such as in-process testing and cell culture sampling, sterile fluid transfer between vessels, and air removal to eliminate bubbles, ensuring precision and reliability in critical manufacturing steps.
Key Features and Benefits
- Patient Safety and Quality: By maintaining sterility and biocontainment throughout the manufacturing process, CellSHIELD® upholds the highest standards of patient safety and product quality.
- Simplicity and Efficiency: Designed for ease of use, CellSHIELD® ensures simple, repeatable processes that reduce the risk of errors and improve operational efficiency, ultimately lowering costs.
- Minimal Training Required: Engineered for intuitive use, CellSHIELD® minimizes the need for extensive training, enabling faster onboarding and productivity.
- Proven CSTD Expertise: Leveraging EQUASHIELD®'s expertise in Closed System Transfer Devices (CSTD), CellSHIELD® brings the same trusted safety and containment principles to cell and gene therapy manufacturing.
Executive Insights
A leading cell therapy CDMO shared their experience with CellSHIELD®: "We see such low volume loss with CellSHIELD®, that once we switch people over, there really is no comparison. Little to no volume loss, less than 0.1%," said a representative from the company.
"CellSHIELD® represents a significant leap forward in cell and gene therapy manufacturing," said Matt Stuckert, General Manager of EQUASHIELD®. "Our mission has always been to innovate and provide solutions that address the most pressing challenges in healthcare. With CellSHIELD®, we are empowering manufacturers to deliver life-saving therapies more efficiently and safer than ever before."
Jason Dutcher, Director of Strategic Accounts, added, "The launch of CellSHIELD® underscores our commitment to advancing medical treatments through cutting-edge technology. This device not only enhances safety and efficiency, but also supports the scalability required to meet the growing demand for cell and gene therapies."
Showcasing at Cell and Gene Meeting on the Mesa
EQUASHIELD® will be showcasing CellSHIELD® at the Cell and Gene Meeting on the Mesa, taking place October 6-8 in Phoenix, Arizona. Attendees will have the opportunity to learn more about how CellSHIELD® is revolutionizing cell and gene therapy manufacturing.
About EQUASHIELD®
EQUASHIELD® is a global leader in healthcare technology, driven by a commitment to innovation, safety, and efficiency. Renowned for its flagship Closed System Transfer Device (CSTD), which has set the benchmark for protecting healthcare workers and patients during hazardous drug compounding and administration, EQUASHIELD® continues to pioneer transformative solutions. Building on its legacy, the company has expanded into automation to streamline workflows and enhance operational safety. With the development of CellSHIELD®, EQUASHIELD® is advancing cell and gene therapy manufacturing, offering cutting-edge solutions that address critical industry challenges and delivering technologies that empower professionals and improve patient outcomes.
Media Contact
EQUASHIELD®
Email: [email protected]
Website: https://www.equashield.com/products/cellshield/
SOURCE Equashield LLC
Share this article